TAK-994, the first orally available OX2R-selective agonist, also suppressed fragmentation of sleep and cataplexy-like episodes in NT1 model mice, and improved measures of wakefulness and cataplexy in a phase 2 trial of individuals with NT120. The gene discussed is HCRTR2; the disease is Cataplexy.